Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (109)
  3. Review (18)
  4. Research Letter (14)
  5. Editorial (6)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (371)
  2. Center for Hematologic Malignancies (371)
  3. Department of Medicine (371)
  4. Hematologic Malignancies, Division of (371)
  5. Hematology-Oncology Fellows (111)
  6. GSK Faculty (92)

More Groups

People
  1. Martin Tallman (118)
  2. Ross Levine (75)
  3. Aaron Goldberg (43)
  4. Andriy Derkach (33)
  5. Jan Bewersdorf (33)
  6. Christopher Famulare (31)

More People

Years
  1. 2025 (20)
  2. 2024 (45)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (171)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (18)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (186)
  2. Elsevier Inc. (32)
  3. American Society of Clinical Oncology (28)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (371)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes after transplant in relapsed/refractory KMT2Ar (MLLr) and mNPM1 (NPM1c) leukemia patients achieving remissions after menin inhibition: SNDX-5613 (revumenib) Ph1 experience
    Meeting Abstract

    Issa, G. C.; Cuglievan, B.; Stein, E.; Arellano, M. L.; Žucenka, A.; Khera, N.; Stone, R. M.; Thirman, M. J.; DiPersio, J. F.; Karras, N.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Cost-effectiveness of azacitidine and ivosidenib in newly diagnosed older, intensive chemotherapy-ineligible patients with IDH1-mutant acute myeloid leukemia
    Meeting Abstract

    Bewersdorf, J. P.; Patel, K. K.; Goshua, G.; Shallis, R. M.; Podoltsev, N. A.; Stahl, M. F.; Stempel, J. M.; Stein, E.; Huntington, S. F.; Zeidan, A. M.
    Blood (2022)

    Fulltext@MSK | Save
  • The menin inhibitor SNDX-5613 (revumenib) leads to durable responses in patients (Pts) with KMT2A-rearranged or NPM1 mutant AML: Updated results of a phase (Ph) 1 study
    Meeting Abstract

    Issa, G. C.; Aldoss, I.; DiPersio, J. F.; Cuglievan, B.; Stone, R. M.; Arellano, M. L.; Thirman, M. J.; Patel, M. R.; Dickens, D.; Shenoy, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular features associated with response to combination therapy with enasidenib (ENA) plus azacitidine (AZA) in newly diagnosed IDH2-mutated acute myeloid leukemia (AML)
    Meeting Abstract

    Risueño, A.; See, W. L.; DiNardo, C. D.; Döhner, H.; Stein, E.; Fathi, A. T.; Vyas, P.; Quek, L.; Prebet, T.; Gandhi, A. K.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
    Guidelines

    Döhner, H.; Wei, A. H.; Appelbaum, F. R.; Craddock, C.; DiNardo, C. D.; Dombret, H.; Ebert, B. L.; Fenaux, P.; Godley, L. A.; Hasserjian, R. P.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Investigational venetoclax combination therapy in acute myeloid leukemia - A systematic review and meta-analysis
    Research Letter

    Shimony, S.; Rozental, A.; Bewersdorf, J. P.; Goldberg, A. D.; Stein, E. M.; Grimshaw, A. A.; Stone, R. M.; DeAngelo, D. J.; Wolach, O.; Stahl, M.
    Haematologica (2022)

    Fulltext@MSK | Save
  • Recent progress in acute leukemia and myelodysplasia
    Review

    Carraway, H. E.; Pollyea, D. A.; Stein, E. M.
    Best Practice and Research: Clinical Haematology (2022)

    Fulltext@MSK | Save
  • Tamibarotene in combination with venetoclax and azacitidine in previously untreated adult patients selected for RARA-positive AML who are ineligible for standard induction therapy (SELECT AML-1)
    Meeting Abstract

    Stein, E.; De Botton, S.; Pigneux, A.; McMahon, C.; Ball, B.; Borthakur, G.; Eghtedar, A.; Kambhampati, S.; Tache, J.; Wang, E. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Ivosidenib in patients with IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS): Updated enrollment and results of a phase 1 dose-escalation and expansion substudy
    Meeting Abstract

    Sallman, D. A.; Foran, J. M.; Watts, J. M.; Stein, E.; De Botton, S.; Fathi, A. T.; Prince, G. T.; Stone, R. M.; Patel, P. A.; Roboz, G. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial
    Meeting Abstract

    De Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Dohner, H.; Fathi, A. T.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save